E. Turpin

发表

High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.

A. Vincent-Salomon, O. Delattre, M. Stern, 2009, Cancer research.

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches

M. Espié, A. Roquancourt, A. de Roquancourt, 2011, British Journal of Cancer.

Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.

H. Soliman, H. de Thé, E. Turpin, 2012, Urologic oncology.

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.

M. Espié, C. Sotiriou, C. Desmedt, 2010, The oncologist.

Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy

M. Espié, A. Roquancourt, M. Marty, 2002, The Lancet.

Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma.

J. Cayuela, C. Gisselbrecht, Weili Zhao, 2004, Blood.

Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers

A. Roquancourt, M. Marty, A. Janin, 1999, Oncogene.

p53 in breast cancer subtypes and new insights into response to chemotherapy.

Raphaël Porcher, Marc Espié, Philippe Bertheau, 2013, Breast.

counts in follicular lymphoma Prognostic significance of bcl-xL gene expression and apoptotic cell

J. Cayuela, N. Mounier, A. Janin, 2013 .

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen

M. Espié, D. Rickman, A. de Roquancourt, 2007, PLoS medicine.

TP53 Status and Response to Chemotherapy in Breast Cancer

Jacqueline Lehmann, Marc Espié, Philippe Bertheau, 2008, Pathobiology.

Changes in allelic imbalances in locally advanced breast cancers after chemotherapy

M. Espié, A. de Roquancourt, J. Misset, 2007, British Journal of Cancer.

p53 dependent cell‐cycle arrest triggered by chemotherapy in xenografted breast tumors

M. Poupon, J. Lehmann-Che, H. de Thé, 2009, International journal of cancer.

Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer

M. Espié, A. Roquancourt, I. Bièche, 2002, Oncogene.

Complete pathological response according to hormonal status, c-erbB2 and P53 in two neoadjuvant treatments in locally advanced breast cancers.

M. Espié, A. Roquancourt, M. Marty, 2009 .

Allelic Loss Detection in Inflammatory Breast Cancer: Improvement with Laser Microdissection

A. Roquancourt, R. Lidereau, A. Janin, 2001, Laboratory Investigation.

Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma.

J. Cayuela, C. Gisselbrecht, Weili Zhao, 2004, Blood.

[Exquisite sensitivity of TP53 mutant breast cancers to dose-dense chemotherapy].

M. Espié, J. Lehmann-Che, H. de Thé, 2007, Medecine sciences : M/S.